Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 453, Issue C, Pages 88-95Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2017.04.026
Keywords
Vitamin D; VDR; Breast cancer; Mammary gland; CYP24A1; CYP27B1; Metabolism
Categories
Funding
- NIH [CA9700, CA144963, CA166434, CA19450]
Ask authors/readers for more resources
The nuclear receptor for 1 alpha,25-dihydroxycholecalciferol (1,25D), the active form of vitamin D, has antitumor actions in many tissues. The vitamin D receptor (VDR) is expressed in normal mammary gland and in many human breast cancers suggesting it may represent an important tumor suppressor gene in this tissue. When activated by 1,25D, VDR modulates multiple cellular pathways including those related to energy metabolism, terminal differentiation and inflammation. There is compelling pre-clinical evidence that alterations in vitamin D status affect breast cancer development and progression, while clinical and epidemiological data are suggestive but not entirely consistent. The demonstration that breast cells express CYP27B1 (which converts the precursor vitamin D metabolite 25D to the active metabolite 1,25D) and CYP24A1 (which degrades both 25D and 1,25D) provides insight into the difficulties inherent in using dietary vitamin D, sun exposure and/or serum biomarkers of vitamin D status to predict disease outcomes. Emerging evidence suggests that the normally tight balance between CYP27B1 and CYP24A1 becomes deregulated during cancer development, leading to abrogation of the tumor suppressive effects triggered by VDR. Research aimed at understanding the mechanisms that govern uptake, storage, metabolism and actions of vitamin D steroids in normal and neoplastic breast tissue remain an urgent priority. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available